Incyte (INCY) Revenue — Quarter Ended Jun 30, 2024
Revenue increased in the current quarter compared with both the prior quarter and the same quarter last year. The sequential and year-over-year growth rates were both positive.
Key takeaway
Quarter ended Jun 30, 2024 · FY2024 Q2
Revenue increased in the current quarter compared with both the prior quarter and the same quarter last year. The sequential and year-over-year growth rates were both positive.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1B
Revenue reported for this quarter.
Quarter-over-quarter
+18.5%
Change from the immediately preceding quarter.
Year-over-year
+9.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$3.9B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2023 | $919M | +11.6% |
| Dec 31, 2023 | $1B | +9.3% |
| Mar 31, 2024 | $880.9M | +8.9% |
| Jun 30, 2024 | $1B | +9.3% |
Revenue performance
Reported revenue rose from the immediately preceding quarter, continuing an upward trend. The year-ago comparison also showed an increase.
Quarterly comparison
Compared with the prior quarter, revenue improved, and it was also higher than the same quarter one year earlier. Sequential and annual growth rates were both reported.
What to watch
The filing notes that a generic version of JAKAFI has been challenged under the Hatch-Waxman Act, with a notice letter received in February 2024.